⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 14, 2024Open Access

Figure 3 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

Rémi Vernet Eugenio Fernández Denis Migliorini Virginie Ancrenaz Emily Charrier Marie‐Claude Belkouch Olivier Von Rohr Muriel Urwyler Claudio De Vito Jessica Renaux Jean Villard Olivier Rubin Julien Grogg Nicolas Mach

View Full Paper

Ask AI

Bookmark

Share

Abstract

Antitumor activity of MVX-ONCO-1. A, Waterfall plot of the maximum percentage of tumor size change in each patient. B, Percentage changes from baseline of tumor size (sum of longitudinal change of recorded lesions) over time in each patient.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vernet et al. (2024) studied this question.

synapsesocial.com/papers/68e5c62db6db64358755d304 https://doi.org/10.1158/2767-9764.26644223

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure 4 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024
2Figure 1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024
3Table 3 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024
4Table 3 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024
5Table 4 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024

Table 4 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024
Figure 2 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024
Table 1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors2024